<DOC>
	<DOCNO>NCT00011362</DOCNO>
	<brief_summary>Infants breathe support often treat steroid ( dexamethasone ) ; however , best timing therapy know . This trial look benefit hazard start dexamethasone therapy two week age four week age premature infant .</brief_summary>
	<brief_title>Dexamethasone Therapy VLBW Infants Risk CLD</brief_title>
	<detailed_description>Ventilator-dependent premature infant often treat dexamethasone . However , optimal timing therapy unknown . We compare benefit hazard initiate dexamethasone therapy two week age four week age 371 ventilator-dependent very-low-birth-weight infant ( 501 1500 gram ) respiratory-index score ( mean airway pressure x fraction inspire oxygen ) great equal 2.4 two week age . The primary outcome number day randomization extubation require reintubation ( extubation score death ) . The secondary outcome death discharge hospital ; duration assist ventilation , supplementary oxygen therapy hospital stay ; incidence chronic lung disease ( define need supplemental oxygen 36 week postconceptional age best obstetrical estimate ) rate morbidity mortality respiratory cause first year . Additional secondary endpoint hyperglycemia , hypertension , growth , bacteremia , necrotizing enterocolitis upper GI bleeding . The sample size 370 base 0.60 probability extubation score late treatment great early treatment , 5 % two-sided type 1 error , 85 % power , 10 % treatment noncompliance . Infants randomize either receive dexamethasone two week follow saline placebo two week , saline placebo two week follow either dexamethasone additional placebo two week ( still meet entry criterion ) . Dexamethasone give dose 0.25 mg per kilogram body weight twice daily intravenously orally five day , dose taper . The median time ventilator independence 36 day dexamethasone-placebo group 37 day placebo-dexamethasone group . The incidence chronic lung disease ( define need oxygen supplementation 36 week postconceptional age ) 66 percent 67 percent , respectively . Dexamethasone associate increased incidence nosocomial bacteremia ( relative risk , 1.5 ; 95 percent confidence interval , 1.1 2.1 ) hyperglycemia ( relative risk , 1.9 ; 95 percent confidence interval , 1.2 3.0 ) dexamethasone-placebo group , elevate blood pressure ( relative risk , 2.9 ; 95 percent confidence interval , 1.2 6.9 ) placebo-dexamethasone group , diminish weight gain head growth ( P less 0.001 ) group . Treatment ventilator-dependent premature infant dexamethasone two week age hazardous beneficial treatment four week age .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : 501 1500 gram 13 15 day old Respiratoryindex score great equal 2.4 increase minimally decrease previous 48 hour score great equal 4.0 even improvement precede 48 hour Exclusion criterion : Received glucocorticoid treatment birth Had evidence suspicious sign sepsis judge treat physician Major congenital anomaly cardiovascular , pulmonary , central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Days</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>NICHD Neonatal Research Network</keyword>
	<keyword>Extremely Low Birth Weight ( ELBW )</keyword>
	<keyword>Prematurity</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Respiratory Distress Syndrome</keyword>
	<keyword>Respiratory insufficiency</keyword>
	<keyword>Steroids</keyword>
</DOC>